myeloabl combin chemotherapi total bodi irradi neuroblastoma myeloabl treatment intensif patient month age stage IV neuroblastoma sequenti deliveri cisplatin radiat cgi primari site adjac lymph node carmustin bcnu melphalan VP seventy-two hour last dose VP tumor-fre mumol/l autolog bone marrow abmt acut toxic grade oral mucos diarrhea fever patient infus unpurg reserv autograft abmt patient group progression-fre month month median month diagnosi progression-fre month month median month therapi month month post-abmt die toxic candidiasi metabol derang venoocclus diseas vod event-fre surviv group patient month post-abmt nine patient group II second remiss abmt transplant procedur progression-fre month month therapi month month post-abmt die toxic aspergillosi hemorrhag cystiti vod relaps primari site benefici effect local radiat term surviv toxic advantag melphalan thiotepa evid regimen surviv patient poor-risk neuroblastoma concern late relaps toxic effort altern riski benefici approach definit ablat neuroblastoma 